4D Molecular Therapeutics Inc(FDMT) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 28 at 4:46 PM ET (Korea 10/29 05:46)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -2.72 | Insider Own | 8.62% | Shs Outstand | 55.2M | Perf Week | 2.46% |
| Market Cap | 0.71B | Forward P/E | - | EPS next Y | 1.37% | Insider Trans | -8.05% | Shs Float | 50.5M | Perf Month | -10.77% |
| Enterprise Value | 0.39B | PEG | - | EPS next Q | -1.05 | Inst Own | 99.63% | Short Float | 22.84% | Perf Quarter | 28.4% |
| Income | -0.18B | P/S | 7.76 | EPS this Y | -71.53% | Inst Trans | 16.8% | Short Ratio | 11.68 | Perf Half Y | 46.77% |
| Sales | 0.09B | P/B | 1.75 | EPS next 5Y | -15.85% | ROA | -37.09% | Short Interest | 11.53M | Perf YTD | 72.4% |
| Book/sh | 7.38 | P/C | 1.98 | EPS past 3/5Y | 10.05% -2.62% | ROE | -43.25% | 52W High | -23.63% ($16.93) | Perf Year | 8.02% |
| Cash/sh | 6.54 | P/FCF | - | Sales past 3/5Y | 200.86% 44.32% | ROIC | -40.58% | 52W Low | 85.78% ($6.96) | Perf 3Y | 23.5% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 26.59% | Gross Margin | 91.17% | Volatility(W/M) | 10.15% 7.26% | Perf 5Y | -58.09% |
| Dividend TTM | - | EV/Sales | 4.26 | Sales Y/Y TTM | 278712.12% | Oper. Margin | -214.24% | ATR (14) | 0.96 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 8.03 | EPS Q/Q | -6.2% | Profit Margin | -194.74% | RSI (14) | 51.01 | Recom | 1.25 |
| Dividend Gr. 3/5Y | - | Current Ratio | 8.03 | Sales Q/Q | 25106.67% | SMA20 | 3.13% ($12.54) | Beta | 2.89 | Target Price | $28.09 |
| Payout | - | Debt/Eq | 0.1 | Earnings | 2026/8/13 | SMA50 | -6.84% ($13.88) | Rel Volume | 1.21 | Prev Close | $11.96 |
| Employees | 196 | LT Debt/Eq | 0.08 | EPS/Sales Surpr. | -2.29% 4.45% | SMA200 | 19.37% ($10.83) | Avg Volume(3M) | 0.99M | Price | $12.93 |
| IPO | 2020/12/11 | Option/Short | Yes/Yes | Trades | 7882 | Volume | 1,189,743 | Change | 8.11% |
🧬 4D Molecular Therapeutics trades under the ticker FDMT and is a US-based, clinical-stage biotech company developing gene therapies built on its proprietary directed evolution platform for adeno-associated virus (AAV) vectors. It is advancing its candidates with a focus on ophthalmic diseases and cystic fibrosis, pursuing a next-generation gene therapy approach designed to deliver lasting therapeutic effects from a single dose.
Over the past 1 year, roughly in the middle
24% below its 1-year high.
Traded about as much as usual. That is 121% of its average volume.
FDMT has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -71.5% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $776. Peers typically go for $1,237.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -58.1%. The S&P 500 did +69% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Short interest is a burden
22.8% of the float is sold short.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #187 of 594 in the industry
Based on market cap of $714M.
ATTO#185 Attovia Therapeutics Inc $721M PER - 
WVE#186 Wave Life Sciences Inc $718M PER - FDMT#187 4D Molecular Therapeutics Inc $714M PER - 
ACHV#188 Achieve Life Sciences Inc $705M PER - 
IAM#189 Iambic Therapeutics Inc $701M PER - 
FAQ
What kind of company is FDMT?
FDMT belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of FDMT?
The market cap of FDMT is approximately $714M, ranking 2,866 within its sector.
What is the 52-week high and low for FDMT?
FDMT has recorded a 52-week high of $16.93 and a low of $6.96.
